Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Expanded Access Protocol to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus

Trial Profile

An Open Label, Expanded Access Protocol to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexanolone (Primary)
  • Indications Status epilepticus
  • Focus Expanded access; Registrational; Therapeutic Use
  • Acronyms Study 302
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 10 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 23 Feb 2017 According to a SAGE Therapeutics media release, data from this and other trials in phase III development program will support Marketing Authorisation Application (MAA) for brexanolone to the European Medicine Agency.
    • 20 Apr 2015 The results from this trial, along with results from SAGE's phase III placebo-controlled STATUS trial and other clinical data obtained from the SAGE-547 development program, are intended to form the basis of an NDA submission for SAGE-547, according to a SAGE Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top